Modulating T-cell response: Innovations in AAV8 gene therapy for retinal diseases

FHS
July 19, 2024
4:56 am

A new study shows that subretinal adeno-associated virus 8 (AAV8) injections cause proinflammatory T-cell immune response against the transgene product.

Merck’s next big thing is (probably) on the way

New biotech newsletter launching this Thursday. Don’t miss out. Hello, everyone. Damian here with a look at a pivotal FDA approval, good news for a small

March 26, 2024

Medtronic identifies cybersecurity vulnerability in cardiac data system

Dive Brief: Medtronic has found a cybersecurity vulnerability in an optional messaging feature in its Paceart Optima cardiac device data workflow system and reported the

July 5, 2023

Adjuvant Immunotherapy in Early-Stage NSCLC

Adjuvant chemotherapy has been the standard of care for patients with resectable non-small cell lung cancer (NSCLC), but newer therapies are entering the mix as

June 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.